NCT00325351已完成2 期
Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 45
- 主要终点
- Response to treatment with ZK-Epo after 6 cycles
研究概览
简要总结
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
详细描述
This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is sponsoring this trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Must have evidence of ovarian cancer measurable by computed tomography (CT) scan or by CA125 blood levels- No radiation therapy in last 4 weeks- No chemotherapy in last 24 weeks - No immunotherapy in last 4 weeks- Good response after previous treatment with carboplatin or cisplatin and then the ovarian cancer got worse again after at least 6 months- Additional criteria determined at screening visit
排除标准
- •Having had more than one treatment regimen with carboplatin or cisplatin- Prior treatment with other epothilones (e.g. ixabepilone)- Use of any investigational drug in the last 4 weeks- Previous radiation to the whole pelvis- Symptomatic brain tumors requiring radiation to the brain - Active infection- Pregnant or breast feeding- Additional criteria determined at screening visit
研究组 & 干预措施
Arm 1
Experimental
干预措施: Sagopilone (ZK 219477) + carboplatin (Drug)
结局指标
主要结局
Response to treatment with ZK-Epo after 6 cycles
时间窗: After 6 cycles
次要结局
- Safety and tolerability of ZK-Epo given with carboplatin(Sept. 2008)
研究者
相似试验
已完成
2 期
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate CancerProstate CancerNCT00350051Bayer53
已完成
2 期
Evaluation of a New Agent for Treatment of Advanced Stage Breast CancerBreast NeoplasmNCT00313248Bayer65
已完成
2 期
Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic MelanomaMelanomaNCT00598507H. Lee Moffitt Cancer Center and Research Institute35
已完成
2 期
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung CancerCarcinoma, Non Small Cell LungNCT00160069Bayer128
终止
2 期
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain MetastasesCNS DiseaseBreast CancerNCT00496379Nancy Lin, MD15